×
MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients
https://clinicaltrials.gov/ct2/show/NCT04525404

Sep 24th, 2021 - Participants with newly or recently diagnosed COVID-19 infection (inpatients and outpatients) will undergo multi-organ MRI (heart, brain, lungs, liver), blood work, and functional testing at one or more time points. Functional testing will include olfaction testing, cognitive testing, spiromety, and a walk test.

Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers
https://clinicaltrials.gov/ct2/show/NCT04594395

Sep 24th, 2021 - This is a cross-sectional study performed annually over 3 years to procure blood samples by fingerstick from healthy individuals living in the Phnom Penh area to evaluate seroprevalence to SARS-CoV-2. A mobile unit will move between various markets, schools, hospitals, clinics, parks, and other public places with local authority permissions. Participants with a positive result on the screening ...

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19
https://clinicaltrials.gov/ct2/show/NCT04592549

Sep 24th, 2021 - The primary objective of this study is to assess the safety and tolerability of escalating IM doses of ADM03820 in healthy adults. Secondary objectives include assessing the pharmacokinetic characteristics and immunogenicity.

Intensive Care Therapy of Covid-19 Disease in Germany
https://clinicaltrials.gov/ct2/show/NCT04455451

Sep 24th, 2021 - Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
https://clinicaltrials.gov/ct2/show/NCT04909879

Sep 24th, 2021 - This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to COVID-19 infection. Subjects will be randomized 2:1 to receive COVI-MSC or placebo. COVI-MSC or placebo will be administered intravenously on Day ...

Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04776044

Sep 24th, 2021 - After being informed about the study and potential risks, all patients giving written informed consent will be undergoing a 1-day screening to determine eligibility for study entry. At day 1, patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to ATR-002 (900mg day 1, 600mg days 2 - 6) or placebo (once daily)

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes
https://clinicaltrials.gov/ct2/show/NCT04816682

Sep 24th, 2021 - According to the Bosch-Barrera et al. paper of 2021, silibinin in a daily dose of more than 1000 mg could improve clinical course of COVID-19 by its dual action: 1.direct inhibition of SARS-CoV-2 replication as well as 2.modulation of innate immune response - 2a. its initial (hyper)inflammation as well as 2b. later reparative phase, respectively. Moreover, the drug is known for its safety and h...

Opioid Use Disorder in the Emergency Department: CTN 0069
https://clinicaltrials.gov/ct2/show/NCT03023930

Sep 24th, 2021 - The study uses a Hybrid Type 3 Effectiveness-Implementation framework and a modified stepped wedge design. The study will be conducted at four EDs with a high prevalence of patients with untreated opioid use disorder (OUD). The four sites will receive the same sequence of evaluations and interventions: the baseline evaluation period after the standard dissemination practice, the IF phase, and c...

COVID-19 Vaccination Take-Up
https://clinicaltrials.gov/ct2/show/NCT04867174

Sep 24th, 2021 - In this work, the investigators are partnering with Contra Costa Health Services (CCHS), the department of health in Contra Costa County, CA, to measure COVID-19 vaccinations and other COVID-19 related preventive health behaviors in the county's Medicaid managed care population. This work will test ways to increase COVID-19 vaccine uptake. The investigators hypothesize that small financial ince...

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
https://clinicaltrials.gov/ct2/show/NCT04847596

Sep 24th, 2021 - This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the...

Liver Function Test Abnormalities in COVID-19
https://clinicaltrials.gov/ct2/show/NCT04763395

Sep 24th, 2021 - This retrospective study will be conducted on 100 patients who were diagnosed as SARS COVID19 positive. The data will be collected from patient records in COVID19 isolation hospitals in Sohag governorate and isolation department in Sohag university hospitals during the period from the start of June 2020 to the end of July 2020. The study protocol will be approved by the Scientific Research Ethi...

The VIDA After COVID Study
https://clinicaltrials.gov/ct2/show/NCT04945590

Sep 24th, 2021 - The purpose of this study is to objectively identify and address social determinants of health (SDOH) priorities and barriers in Latino patients who survived or are vulnerable to COVID-19, and to understand the consequences of COVID-19 survivorship in local Latino communities.

The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change
https://clinicaltrials.gov/ct2/show/NCT04896060

Sep 24th, 2021 - We will recruit previous NIDDK study participants as well as newly recruited individuals from the general population to examine how the COVID-19 pandemic has exacerbated the impact of psychosocial stressors that impact eating behavior and weight. The study will describe the relationship between specific COVID-19 related stressors (e.g. fear of becoming sick) and self-rated measures of food inse...

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
https://clinicaltrials.gov/ct2/show/NCT04884685

Sep 24th, 2021 - This study is a randomized, double-blinded, placebo-controlled,phase Ⅱb clinical trial in children and adolescents aged 3-17 years. The experimental vaccine and placebo were both manufactured by Sinovac Research and Development Co., Ltd.. A total of 500 subjects will be enrolled, including 100 children aged 3-5 years, 200 children aged 6-11 years and 200 adolescents aged 12-17 years. Each age g...

Natural History Study of COVID-19 Using Digital Wearables
https://clinicaltrials.gov/ct2/show/NCT04927442

Sep 24th, 2021 - Covid-19 patients experience varying degrees of illness, ranging from no/mild symptoms to critical illness/death. A subset of covid-19 patients experiences long-term sequelae of covid-19 regardless of the severity of the disease initially. Predicting where a patient falls on the illness spectrum is important to allocate sparse resources and intervene medically at an optimal time. With current r...

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
https://clinicaltrials.gov/ct2/show/NCT04852289

Sep 24th, 2021 - This study is to identify SARS-CoV-2 S protein specific CD8 T cells in the blood of COVID-19 vaccinated participants. Pfizer and Moderna made vaccines will be used in this study. As both vaccines are mRNA based encoding S protein of SARS-CoV-2 and require two doses, the CD8 T cell response is expected to be comparable. We will also measure general health factors using blood samples. By analyzin...

Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
https://clinicaltrials.gov/ct2/show/NCT04930978

Sep 24th, 2021 - Coronavirus disease (COVID-19) is a new respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family coronaviridae with wide spreading in humans and animals. This virus is enveloped and contains positive-sense, single-stranded RNA with approximately 31 kb of genome size and so far, is considered as the largest known RNA virus...

Emotional, Social, Cognitive and Behavioral Sequalae of the COVID-19 Pandemic
https://clinicaltrials.gov/ct2/show/NCT04823988

Sep 24th, 2021 - Title: Emotional, Social, Cognitive and Behavioral sequalae of the COVID-19 pandemic Study Description: The goal of this protocol is to examine individual consequences of the COVID-19 pandemic, in the transition resolution phase with the arrival and distribution of the vaccine. Specifically, this protocol will capture the 'after-effects' of the pandemic at all levels of functioning (cognitive, ...

Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland
https://clinicaltrials.gov/ct2/show/NCT04823182

Sep 24th, 2021 - Approximately 100 participants from primary care will be enrolled via General Practitioner (GP) or Primary Care Centers in Dublin. A patient information sheet (PIS) will be made accessible to participants recovering from COVID-19 via their GP practice inviting the participants to contact Cardiovascular Research Institute Dublin. The participants, subject to suitability, will be invited for a si...

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
https://clinicaltrials.gov/ct2/show/NCT04962308

Sep 24th, 2021 - This study is an open-label phase Ⅳ clinical trial in healthy adult aged 18-59 years. The experimental vaccine was manufactured by Sinovac Research and Development Co.,Ltd.. A total of 1400 subjects will be enrolled,the safety and immunogenicity of booster immunization were evaluated in 400 subjects (group A) who received two doses of primary immunization at an interval of 21 to 31 days. And th...